Bevatas 100mg Injection

About

Bevacizumab is a recombinant humanized monoclonal antibody that specifically binds to and neutralizes vascular endothelial growth factor (VEGF). VEGF is a key mediator of angiogenesis, the process by which new blood vessels are formed. By inhibiting VEGF, bevacizumab prevents the formation of new blood vessels that tumors need to grow and metastasize, effectively starving the tumor of oxygen and nutrients. This anti-angiogenic action makes it a valuable therapeutic agent in the treatment of various solid tumors, often used in combination with chemotherapy regimens.

Its mechanism of action targets the tumor microenvironment rather than directly cytotoxic effects on cancer cells, leading to a distinct side effect profile compared to traditional chemotherapy. Bevacizumab is administered intravenously and requires careful monitoring for potential adverse events, particularly those related to its anti-angiogenic properties such as hypertension, proteinuria, and bleeding. It represents a significant advancement in targeted cancer therapy, improving outcomes for patients with advanced or metastatic disease.

Uses

• Treatment of metastatic colorectal cancer.
• Management of non-small cell lung cancer.
• Used in glioblastoma multiforme.
• Treatment of metastatic renal cell carcinoma.

Directions For Use

Administered intravenously by a healthcare professional. Dosage and frequency are determined by the physician based on the specific cancer type and patient's body weight.

Benefits

• Inhibits tumor growth by cutting off blood supply.
• Extends progression-free survival in various cancers.
• Can be combined with standard chemotherapy.
• Reduces tumor size and disease burden.
• Offers a targeted approach to cancer treatment.
• Improves overall survival in eligible patients.

Side Effects

• Hypertension
• Proteinuria
• Bleeding (hemorrhage)
• Thromboembolic events
• Gastrointestinal perforation
• Wound healing complications
• Fatigue
• Headache
• Diarrhea
• Nausea
• Taste alteration
• Nasal septum perforation

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but moderation is generally advised during cancer treatment.
• Pregnancy - Bevacizumab is contraindicated in pregnancy due to potential fetal harm. Effective contraception is required during treatment and for a period after.
• Breastfeeding - Breastfeeding is not recommended during bevacizumab treatment and for a period after, as the drug may pass into breast milk and harm the infant.
• Liver - Use with caution in patients with hepatic impairment; no specific dose adjustment guidelines, but monitor liver function.
• Kidney - Use with caution in patients with renal impairment; monitor for proteinuria and kidney function.
• Lung - Use with caution in patients with a history of hemoptysis or pulmonary hemorrhage; monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.